-transparent.png){kind=logo}
Zidovudine (AZT) is of some benefit for selected patients with AIDS-related complex (ARC) or AIDS treated for up to 24 weeks. The activity and toxicity of oral AZT, 200 mg 4-hourly when possible, was evaluated in 365 consecutive patients with ARC (80) or AIDS (285) followed up for a mean of 31 weeks (range 2-52). A transient increase in body weight, Karnofsky index, and CD4 cell count was observed during the first months of therapy. However, by 6 months, these values had returned to their pretreatment levels and several opportunistic infections, malignancies, and deaths occurred. These disappointing results were partly related to the haematological toxicity of the drug, which led to interruption of treatment in many patients. Thus the benefits of AZT are limited to a few months for ARC and AIDS patients. At least for the most severely affected patients, reduced dosage of AZT may increase the therapeutic index.
E Dournon, and
S Matheron, and
W Rozenbaum, and
S Gharakhanian, and
C Michon, and
P M Girard, and
C Perronne, and
D Salmon, and
P De Truchis, and
C Leport
November 1989,
Clinical pharmacology and therapeutics,
E Dournon, and
S Matheron, and
W Rozenbaum, and
S Gharakhanian, and
C Michon, and
P M Girard, and
C Perronne, and
D Salmon, and
P De Truchis, and
C Leport
March 1993,
Annals of internal medicine,
E Dournon, and
S Matheron, and
W Rozenbaum, and
S Gharakhanian, and
C Michon, and
P M Girard, and
C Perronne, and
D Salmon, and
P De Truchis, and
C Leport
December 1992,
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
E Dournon, and
S Matheron, and
W Rozenbaum, and
S Gharakhanian, and
C Michon, and
P M Girard, and
C Perronne, and
D Salmon, and
P De Truchis, and
C Leport
May 1988,
JAMA,
E Dournon, and
S Matheron, and
W Rozenbaum, and
S Gharakhanian, and
C Michon, and
P M Girard, and
C Perronne, and
D Salmon, and
P De Truchis, and
C Leport
August 1992,
AIDS (London, England),
E Dournon, and
S Matheron, and
W Rozenbaum, and
S Gharakhanian, and
C Michon, and
P M Girard, and
C Perronne, and
D Salmon, and
P De Truchis, and
C Leport
December 1988,
The New England journal of medicine,
E Dournon, and
S Matheron, and
W Rozenbaum, and
S Gharakhanian, and
C Michon, and
P M Girard, and
C Perronne, and
D Salmon, and
P De Truchis, and
C Leport
January 1991,
BMJ (Clinical research ed.),
E Dournon, and
S Matheron, and
W Rozenbaum, and
S Gharakhanian, and
C Michon, and
P M Girard, and
C Perronne, and
D Salmon, and
P De Truchis, and
C Leport
August 1990,
AIDS (London, England),
E Dournon, and
S Matheron, and
W Rozenbaum, and
S Gharakhanian, and
C Michon, and
P M Girard, and
C Perronne, and
D Salmon, and
P De Truchis, and
C Leport
August 1986,
Lancet (London, England),
E Dournon, and
S Matheron, and
W Rozenbaum, and
S Gharakhanian, and
C Michon, and
P M Girard, and
C Perronne, and
D Salmon, and
P De Truchis, and
C Leport
November 1989,
JAMA,
